NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported ($0.60) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.60). The biopharmaceutical company had revenue of $12.85 million for the quarter, compared to analyst estimates of $12.75 million. View Alimera Sciences' Earnings History.

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Alimera Sciences.

3 brokerages have issued 1 year target prices for Alimera Sciences' shares. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' stock price to reach $30.00 in the next year. This suggests a possible upside of 399.2% from the stock's current price. View Analyst Price Targets for Alimera Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.

Media headlines about ALIM stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alimera Sciences earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Alimera Sciences.

Alimera Sciences saw a drop in short interest during the month of February. As of February 14th, there was short interest totalling 22,700 shares, a drop of 28.8% from the January 30th total of 31,900 shares. Based on an average daily volume of 64,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.6% of the company's stock are sold short. View Alimera Sciences' Current Options Chain.

Some companies that are related to Alimera Sciences include ProMetic Life Sciences (PFSCF), Cassava Sciences (SAVA), Millendo Therapeutics (MLND), Aldeyra Therapeutics (ALDX), Galmed Pharmaceuticals (GLMD), Sierra Oncology (SRRA), NeuBase Therapeutics (NBSE), PhaseBio Pharmaceuticals (PHAS), Helix Biopharma (HBPCF), Adamas Pharmaceuticals (ADMS), Galectin Therapeutics (GALT), Menlo Therapeutics (MNLO), TapImmune (MRKR), AcelRx Pharmaceuticals (ACRX) and Chimerix (CMRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), CorMedix (CRMD), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD).

Alimera Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Palo Alto Investors LP (4.04%), Renaissance Technologies LLC (1.52%), Royce & Associates LP (0.93%), JW Asset Management LLC (0.55%) and Geode Capital Management LLC (0.21%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.

ALIM stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, Royce & Associates LP, JW Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Alimera Sciences.

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALIM stock can currently be purchased for approximately $6.01.

Alimera Sciences has a market capitalization of $29.85 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences.

The official website for Alimera Sciences is http://www.alimerasciences.com/.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]